Sukumar Nagendran's most recent trade in Taysha Gene Therapies Inc was a trade of 260,047 Employee Stock Option (right to buy) done . Disclosure was reported to the exchange on Nov. 28, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Taysha Gene Therapies Inc | Sukumar Nagendran | Director, President and Head of R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Nov 2025 | 260,047 | 563,617 | - | - | Employee Stock Option (right to buy) | |
| Taysha Gene Therapies Inc | Sukumar Nagendran | Director, President and Head of R&D | Sale of securities on an exchange or to another person at price $ 4.51 per share. | 28 Nov 2025 | 260,047 | 1,006,439 | - | 4.5 | 1,172,812 | Common Stock |
| Taysha Gene Therapies Inc | Sukumar Nagendran | Director, President and Head of R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.71 per share. | 28 Nov 2025 | 260,047 | 1,266,486 | - | 1.7 | 444,680 | Common Stock |
| Taysha Gene Therapies Inc | Sukumar Nagendran | Director, President and Head of R&D | Sale of securities on an exchange or to another person at price $ 4.75 per share. | 28 Nov 2025 | 110,125 | 1,006,439 | - | 4.8 | 523,094 | Common Stock |
| Taysha Gene Therapies Inc | Sukumar Nagendran | Director, President and Head of R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.70 per share. | 28 Nov 2025 | 70,172 | 1,076,611 | - | 0.7 | 49,043 | Common Stock |
| Taysha Gene Therapies Inc | Sukumar Nagendran | Director, President and Head of R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Nov 2025 | 70,172 | 222,683 | - | - | Employee Stock Option (right to buy) | |
| Taysha Gene Therapies Inc | Sukumar Nagendran | Director, President and Head of R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Nov 2025 | 39,953 | 823,664 | - | - | Employee Stock Option (right to buy) | |
| Taysha Gene Therapies Inc | Sukumar Nagendran | Director, President and Head of R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.71 per share. | 28 Nov 2025 | 39,953 | 1,116,564 | - | 1.7 | 68,320 | Common Stock |
| Taysha Gene Therapies Inc | Sukumar Nagendran | Director, President and Head of R&D | Sale of securities on an exchange or to another person at price $ 3.23 per share. | 10 Sep 2025 | 200,000 | 1,006,439 | - | 3.2 | 646,000 | Common Stock |
| Taysha Gene Therapies Inc | Sukumar Nagendran | Director, President and Head of R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Sep 2025 | 41,150 | 292,855 | - | - | Employee Stock Option (right to buy) | |
| Taysha Gene Therapies Inc | Sukumar Nagendran | Director, President and Head of R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.70 per share. | 10 Sep 2025 | 41,150 | 1,206,439 | - | 0.7 | 28,760 | Common Stock |
| Taysha Gene Therapies Inc | Sukumar Nagendran | Director, President and Head of R&D | Sale of securities on an exchange or to another person at price $ 2.85 per share. | 21 Aug 2025 | 57,054 | 1,165,289 | - | 2.9 | 162,604 | Common Stock |
| Solid Biosciences Inc | Sukumar Nagendran | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2025 | 77,500 | 77,500 | - | - | Director Stock Option (Right to Buy) | |
| Taysha Gene Therapies Inc | Sukumar Nagendran | Director, President and Head of R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 324,500 | 324,500 | - | - | Employee Stock Option (right to buy) | |
| Taysha Gene Therapies Inc | Sukumar Nagendran | Director, President and Head of R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 324,500 | 1,222,343 | - | 0 | Common Stock | |
| Solid Biosciences Inc | Sukumar Nagendran | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2024 | 34,400 | 34,400 | - | - | Director Stock Option (Right to Buy) | |
| Taysha Gene Therapies Inc | Sukumar Nagendran | Director, President and Head of R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 863,617 | 897,843 | - | 0 | Common Stock | |
| Taysha Gene Therapies Inc | Sukumar Nagendran | Director, President and Head of R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 863,617 | 863,617 | - | - | Employee Stock Option (right to buy) | |
| Taysha Gene Therapies Inc | Nagendran Sukumar | Director, President and Head of R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Dec 2023 | 334,005 | 334,005 | - | - | Employee Stock Option (right to buy) | |
| Solid Biosciences Inc | Sukumar Nagendran | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2023 | 9,650 | 9,650 | - | - | Director Stock Option (Right to Buy) | |
| Taysha Gene Therapies Inc | Sukumar Nagendran | Director, President and Head of R&D | Purchase of securities on an exchange or from another person at price $ 0.68 per share. | 16 May 2023 | 5,000 | 34,226 | - | 0.7 | 3,400 | Common Stock |
| Taysha Gene Therapies Inc | Sukumar Nagendran | Director, President and Head of R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Dec 2022 | 790,093 | 790,093 | - | - | Stock Option (right to buy) | |
| Solid Biosciences Inc | Sukumar Nagendran | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Dec 2022 | 9,650 | 9,650 | - | - | Director Stock Option (Right to Buy) | |
| Taysha Gene Therapies Inc | Sukumar Nagendran | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2022 | 15,500 | 15,500 | - | - | Stock Option (right to buy) | |
| Solid Biosciences Inc | Sukumar Nagendran | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2022 | 51,000 | 51,000 | - | - | Director Stock Option (Right to Buy) | |
| Taysha Gene Therapies Inc | Sukumar Nagendran | Director | Purchase of securities on an exchange or from another person at price $ 8.01 per share. | 02 Feb 2022 | 10,000 | 29,226 | - | 8.0 | 80,100 | Common Stock |
| Taysha Gene Therapies Inc | Sukumar Nagendran | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2021 | 15,500 | 15,500 | - | - | Stock Option (right to buy) |